Publications by authors named "R Palmero"
Article Synopsis
- - The NADIM trial was a phase 2 study in Spain that evaluated the effects of perioperative immunotherapy on long-term outcomes in patients with stage IIIA non-small-cell lung cancer (NSCLC), showing positive short-term results previously. - A total of 46 treatment-naive patients participated, receiving a combination of chemotherapy and nivolumab before surgery, followed by more nivolumab as adjuvant therapy, with the study measuring 5-year progression-free and overall survival rates. - Findings showed that after 5 years, 65% of patients were progression-free and 69% had overall survival, with disease progression seen in 24% of patients and 30% dying by the end of the follow-up period.
Purpose: Transcriptomic subtyping holds promise for personalized therapy in extensive-stage small cell lung cancer (ES-SCLC). In this study, we aimed to assess intratumoral transcriptomic subtype diversity and to identify biomarkers of long-term chemoimmunotherapy benefit in human ES-SCLC.
Experimental Design: We analyzed tumor samples from 58 patients with ES-SCLC enrolled in two multicenter single-arm phase IIIb studies evaluating frontline chemoimmunotherapy in Spain: n = 32 from the IMfirst trial and n = 26 from the CANTABRICO trial.
Article Synopsis
- The study compares the effectiveness of atezolizumab plus cabozantinib versus docetaxel in patients with advanced non-small cell lung cancer (NSCLC) who did not respond to prior immunotherapy and chemotherapy.
- Results showed similar overall survival rates: 10.7 months for the combination treatment and 10.5 months for docetaxel, with both showing comparable median progression-free survival.
- Adverse events were reported in both treatment groups; however, a higher percentage of serious adverse events occurred in those receiving atezolizumab plus cabozantinib compared to docetaxel.
Background: Targeted next-generation sequencing (NGS) is recommended to screen actionable genomic alterations (GAs) in patients with non-small-cell lung cancer (NSCLC). We determined the feasibility to detect actionable GAs using TruSight™ Oncology 500 (TSO500) in 200 consecutive patients with NSCLC.
Materials And Methods: DNA and RNA were sequenced on an Illumina® NextSeq 550 instrument and processed using the TSO500 Docker pipeline.
Lung adenocarcinoma (LUAD) is a molecularly heterogeneous disease. In addition to genomic alterations, cancer transcriptional profiling can be helpful to tailor cancer treatment and to estimate each patient's outcome. Transcriptional activity levels of 50 molecular pathways were inferred in 4573 LUAD patients using Gene Set Variation Analysis (GSVA) method.
View Article and Find Full Text PDF